Asana BioSciences, LLC

Release Summary

Asana BioSciences announces the first patient dosing in a Phase 1 trial for ASN003, a novel and highly selective B-RAF/phosphoinositide 3-kinase (PI3K) inhibitor targeted to multiple types of cancer

Asana BioSciences, LLC